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Abstract
Background: Trachoma causes blindness through an anatomical abnormality called trichiasis (lashes touching the eye).
Trichiasis can recur after corrective surgery. We tested the hypothesis that using absorbable sutures instead of silk sutures
might reduce the risk of recurrent disease among patients with major trichiasis in a randomised trial.
Methods and Findings: 1,300 individuals with major trichiasis from rural villages in the Amhara Region of Ethiopia were
recruited and assigned (1:1) by computer-generated randomisation sequence to receive trichiasis surgery using either an
absorbable suture (polyglactin-910) or silk sutures (removed at 7–10 days) in an otherwise identical surgical technique.
Participants were examined every 6 months for 2 years by clinicians masked to allocation. The primary outcome measure
was recurrent trichiasis ($one lash touching the eye) at 1 year. There was no difference in prevalence of recurrent trichiasis
at 1 year (114 [18.2%] in the absorbable suture group versus 120 [19.7%] in the silk suture group; odds ratio = 0.90, 95% CI
0.68–1.20). The two groups also did not differ in terms of corneal opacification, visual acuity, conjunctival inflammation, and
surgical complications.
Conclusions: There was no evidence that use of absorbable polyglactin-910 sutures was associated with a lower prevalence
of trichiasis recurrence at 1 year postsurgery than silk sutures. However, from a programmatic perspective, polyglactin-910
offers the major advantage that patients do not have to be seen soon after surgery for suture removal. The postoperative
review after surgery using absorbable polyglactin-910 sutures can be delayed for 3–6 months, which might allow us to
better determine whether a patient needs additional surgery.
Trial registration: http://ClinicalTrials.gov NCT00522860
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Introduction
Trachoma is the leading infectious cause of blindness worldwide
[1]. Recurrent episodes of ocular Chlamydia trachomatis infection in
early childhood provoke chronic conjunctival inflammation (active
trachoma). This inflammation leads to scarring of conjunctival
tissue, which causes the eyelids to roll in (entropion) and the lashes
to scratch the surface of the eye (trachomatous trichiasis [TT]).
Ultimately, blinding corneal opacification (CO) develops from the
persistent abrasion of lashes and secondary bacterial infection.
Blinding trachoma is reported to be prevalent in more than 50
countries [1]. Over 40 million individuals (mostly children) are
estimated to have active trachoma at any one time, 8 million
people have trichiasis and a further 8 million are estimated to be
blind or visually impaired from the disease [1,2]. Ethiopia has the
highest rates of active trachoma and trichiasis in the world, with an
estimated 1.3 million unoperated cases of TT [1]. Endemic
countries are striving to control this disease through the
implementation of the SAFE strategy: surgery for trichiasis,
antibiotics for infection, facial cleanliness and environmental
improvements to reduce transmission [3].
To prevent blindness from trichiasis, surgery is performed to
correct the entropion, lifting the eyelashes off the cornea.
Ophthalmic services are generally limited in trachoma endemic
settings; therefore, specially trained nurses usually perform the
surgery in the community. Several different procedures have been
tried over the last century [4], but trichiasis frequently recurs
either because of some intrinsic limitation or quality of the surgery,
or because of progressive scarring. Studies of trichiasis recurrence
rates following surgery conducted under ‘‘operational’’ conditions
have consistently shown disappointing outcomes, with usually at
least 20% recurrence by 1 y and up to 62% at 3 y [5–11].
Moreover, these poor surgical outcomes undermine other efforts
to prevent blindness from trachoma. Context-appropriate inter-
ventions to improve results are urgently needed.
Several factors contribute to recurrent trichiasis, which can be
divided into early surgery-related and later disease-related factors.
Data from prospective studies suggest that the majority of
recurrent trichiasis develops within 6 mo of surgery, indicating
the importance of how the surgery is performed [5,8,9,12–14].
Randomised controlled trials (RCTs) of alternative procedures
indicate that bilamellar tarsal rotation (BLTR) and posterior tarsal
rotation (PLTR) procedures are associated with the lowest
recurrence rates, leading to the World Health Organization’s
(WHO) recommendation of their use [3,4,12,15,16]. However,
recurrence rates for both procedures are quite high [5–8,17–19].
The quality of surgery is important, indicated by significant
variation in the results of different surgeons [8].
Suture type, positioning, and tension are likely to be important
aspects of surgical technique that contribute to TT recurrence. Silk
sutures are used as standard in trichiasis surgery and need to be
removed 7–10 d postoperatively [16]. At this stage the incision
may not have reached a state of stable wound healing, because of
the scarred nature of the diseased tissue. The use of absorbable
suture materials, such as polyglactin-910, which is commonly used
in ophthalmic and other surgery, may provide more prolonged
and stable fixation of the tissue in the desired position while
healing is taking place [20].
A retrospective review of surgical outcomes in Egypt found that
recurrence rates were significantly lower in individuals who had
received long-lasting absorbable sutures (0.8%) compared to those
with silk sutures (43.5%) [11]. In this current study, we test the
hypothesis that using absorbable polyglactin-910 sutures can
reduce the postoperative trichiasis recurrence rate compared to
the current standard silk sutures, in a randomised trial in Amhara
Region, Ethiopia.
Methods
Ethics Statement
The National Health Research Ethics Review Committee of the
Ethiopian Ministry of Science and Technology, the London
School of Hygiene and Tropical Medicine Ethics Committee, and
Emory University Institutional Review Board approved the trial.
Potential participants were provided with both written and oral
information in Amharic about the trial. For those agreeing to
participate, written informed consent in Amharic was required
prior to enrolment. If the participant was unable to read and write,
the information sheet and consent form were read to them and
their consent recoded by witnessed thumbprint. An independent
Data Safety Monitoring Committee reviewed the trial for patient
safety and there were no deviations from the original protocol. No
interim analyses for efficacy or futility were planned or conducted.
The Trial Protocol is described in Text S1 and the CONSORT
statement in Text S2.
Participants
Eligible participants were individuals aged 18 y or over with
previously unoperated major trichiasis (.five trichiatic eyelashes,
some of which may have been epilated and were regrowing) who
presented during a TT surgical treatment campaign in rural
villages in the West Gojjam zone of the Amhara Region of
Ethiopia from March to June 2008. Exclusion criteria were
previous eyelid surgery, medically unfit, or pregnancy (self-
reported or clearly evident). The surgical campaigns were
advertised in local markets, churches, and schools. Additionally,
health extension workers from the subdistricts (kebele) in the study
area were trained to recognize trichiasis and visited each village in
their kebele to identify patients.
Preoperative Clinical Assessment
The clinical assessments and surgery were performed in
government health centres, clinics, and other suitable buildings.
A field worker administered a questionnaire in Amharic. Height
and weight were measured. Unaided and pinhole LogMAR visual
acuities were measured at 4 m, using an ETDRS equivalent
Tumbling-E LogMAR chart (Hong Kong Low Vision Centre).
The testing distance was reduced to 2 or 1 m if necessary. For
those unable to read the LogMAR chart at 1 m their visual acuity
was tested by counting fingers at 1 m or hand movements at
0.5 m. For visual acuities of counting fingers or less, LogMAR
values were attributed: counting fingers, 2.0; hand movements,
2.5; perception of light, 3.0; no perception of light, 3.5. No patients
had spectacles for distance correction. Ophthalmic examinations
were conducted in a darkened room using 2.56 magnification
loupes and a bright torch. A single ophthalmologist (SNR)
performed all baseline examinations. The number of lashes
touching the eye was counted (‘‘lash burden’’) and also subdivided
by the part of the eye contacted when looking straight ahead:
cornea, lateral conjunctiva, or medial conjunctiva. Clinical
evidence of epilation was identified by the presence of broken or
newly growing lashes, or areas of absent lashes. Upper lid
entropion was graded by assessing the degree of inward rotation of
the eyelid margin (Table S1). The degree of corneal scarring was
classified on the basis of a modified WHO FPC grading system in
which the degree of central corneal scarring (CC2) is subdivided to
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provide more definition (Table S1) [21]. Tarsal conjunctival
papillary inflammation, follicles, and scarring were classified using
the WHO FPC grading system [21]. Standardised high-resolution
digital photographs were taken of each of these features.
Interventions
Following the preoperative clinical assessment, participants
were randomised to one of two surgical intervention groups, which
differed only in the type of sutures that were used. The posterior
lamella tarsal rotation procedure was used in all cases [5]. Surgery
was performed under local anaesthesia administered by subcuta-
neous infiltration of the upper eyelid: 2–3 ml of lidocaine 1%, with
adrenaline. The lid was then everted and the posterior lamella
(tarsal conjunctiva and tarsal plate) incised parallel to and 3 to
4 mm above the lid margin. The posterior lamella was separated
from the anterior lamella (obicularis oculi and skin) by blunt
dissection in the tissue plane. Three sets of everting sutures were
placed running down and forward from the upper cut edge of the
tarsal plate to emerge through the skin just above the eyelashes. As
the sutures are tightened they externally rotate the lower border of
the eyelid. The sutures were either (1) silk, 4/0 (Mersilk, Ethicon)
or (2) polyglactin-910, 5/0 (Vicryl undyed, Ethicon). All sutures
had three-eighth circle, 16-mm cutting needles at each end
(‘‘double ended’’). Postoperatively, the operated eye was padded
for a day and then tetracycline eye ointment was self-administered
twice a day for 2 wk. If the participant had bilateral trichiasis they
were offered surgery to both eyes on the day of enrolment, using
the same randomly allocated suture type for each eye.
Five nurses, who had previously been trained in and were
regularly performing TT surgery, performed the surgery in this
trial. They were selected as the best surgeons from a larger group
of nine during a 2-d standardisation workshop. The training was
conducted by an experienced Ethiopian ophthalmologist (ABK),
who had contributed to the development of the WHO TT surgeon
certification manual [22]. The posterior lamellar tarsal rotation
techniques of the five nurses were carefully observed and
standardised to ensure that all performed the operation in the
same way.
Follow-up Clinical Assessments
All participants were seen 7–10 d postoperatively, when silk
sutures were removed and any complications noted and treated
as needed. Follow-up assessments were conducted at 3, 6, 12, 18,
and 24 mo postoperatively. On each occasion an ophthalmic
examination was performed and digital photographs taken.
Photographs were not taken at 3 mo. Visual acuity was
measured at 12 and 24 mo. The 12-mo and 24-mo follow-up
examinations were conducted by the same single ophthalmolo-
gist (SNR) who performed the preoperative examinations; the 3-,
6-, and 18-mo examinations were conducted by a single
ophthalmic nurse (EH). Neither of these examiners was involved
in performing surgery in this trial. The examiners were
standardised to each other and showed strong agreement
between these two observers for the presence of trichiasis in a
preliminary assessment of 200 eyes (kappa = 0.86) Several
different ophthalmic nurses who did not take part in subsequent
follow-ups conducted the 7-d follow-up. Any individual who
developed significant recurrent trichiasis during the follow-up
period was offered repeat surgery performed by a senior surgeon.
These reoperated individuals continued to be followed up
according to the trial protocol. Individuals in whom other
ophthalmic pathology (e.g., cataract) was detected were referred
to the regional ophthalmic services.
Outcome Measures
The primary outcome measure was the proportion of those
individuals seen at the 12-mo follow-up who were found to have
either (1) recurrent trichiasis, defined as one or more lashes
touching the eye or clinical evidence of epilation, or (2) a history of
repeat TT surgery during the first year. Individuals not seen at
12 mo were excluded from this primary analysis. A priori defined
secondary outcome measures at 12 and 24 mo were: CO, visual
acuity, entropion, and conjunctival inflammation. Change in CO
was determined both from direct comparison of the 1- and 2-y
photographs with the baseline photographs and from the field
grading scores. This enabled us to detect progression or regression
using an alternative method of assessment of corneal opacities.
Randomisation, Allocation Concealment, and Masking
Participants were randomly allocated to the silk or polyglactin-
910 suture arms using a 1:1 allocation ratio for each surgeon, using
a computer-generated randomisation sequence with random block
sizes. Randomisation was stratified by surgeon because of possible
intersurgeon variability (each surgeon had a separate sequence).
The statistician held the master randomisation lists. The random
allocation sequences for each surgeon were concealed in
sequentially numbered, sealed, opaque envelops, which were
placed in separate containers for each surgeon; a person
independent of all other aspects of the trial prepared these
envelopes. On most days during the surgery campaign two or
three surgeons operated simultaneously. Following the baseline
examination, participants were allocated to the next available
surgeon. A trained field worker was responsible for implementing
the intervention assignment in a dedicated area, separated from
those performing the preoperative examinations. The field worker
and surgeon jointly confirmed the suture allocation and recorded
this in the surgical logbook. The same field worker dispensed the
appropriate sutures to the surgeon. Participants and surgeons were
aware of the suture allocation. The two individuals (SNR, EH)
who were responsible for all the clinical observations in this trial
were masked to the allocation. For the purposes of the trial analysis
only one eye per person was considered. If the participant had
bilateral trichiasis operated on, the study eye (for analytical
purposes) was chosen at random using a computer generated
randomisation list.
Statistical Methods
Using a conservative 1-y risk of TT recurrence of 10% in the
silk arm we considered a 50% reduction in recurrence to 5% in the
polyglactin-910 arm to be programmatically significant [8,13]. A
sample of 1,240 participants (620 in each arm) would provide 90%
power and 95% confidence to detect a difference with a relative
risk of 0.5; this was increased to 1,300 to allow for 5% loss to
follow-up.
Data were double entered into an Access (Microsoft) database
and transferred to Stata 11 (StataCorp) for analysis. The analysis
was on an intention-to-treat basis. For participants who had
bilateral surgery only the randomly designated study eye was
included in the analysis. We made every effort to obtain all
outcome data for every participant. We excluded patients from
analyses if they had missing data relevant to a particular analysis,
as indicated in the results. Missing data were not imputed.
The primary outcome (recurrent trichiasis at 12 mo) and
secondary outcomes were compared between the two groups using
logistic regression analyses to estimate the odds ratio (OR) and
95% CI. Time to recurrence was analysed with Kaplan-Meier
survival curves, and Cox regression models were used to estimate
hazard ratios (HRs) and associated 95% CI. Individuals who had
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reached endpoint at a previous time point or were permanently
lost to follow-up from that time onwards were censored. A
multivariable logistic regression model was developed to estimate
OR and 95% CI for associations of any recurrent trichiasis during
the 2 y of follow-up with potential explanatory factors. Variables
that were associated with recurrent trichiasis on univariate analysis
(p,0.2) were retained in the multivariable model. The surgeon
with the lowest recurrence rate at 2 y was used as the reference for
the others in the models.
Results
Participant Recruitment and Flow
Recruitment ran from March–June 2008. Several thousand
people presented with eye complaints during the course of the
surgical outreach campaign and were assessed for eligibility for this
trial. The majority had other ophthalmic conditions such as
cataract. It was not possible to record the total number of
individuals examined who did not have trichiasis. A total of 1,300
consecutive individuals who met the inclusion criteria were
recruited; none were excluded and all consented and were
enrolled in the trial. All 1,300 were randomised and received
their allocated surgical treatment (650 participants in each trial
arm) (Figure 1).
Primary outcome data are available for 608/650 (93.5%)
participants in the silk group and 628/650 (96.7%) of participants
in the polyglactin-910 group (Figure 1). Overall, 69.3%% of
participants were seen at all five scheduled visits over 24 mo (447/
650 [68.8%] in the silk group and 454/650 [69.9%] in the
polyglactin-910 group). At all follow-up time points more than
90% of participants were examined, except for the 3-mo follow-
up, which was limited by the wet season. There was little
difference by randomisation group in the number of times
individuals were seen during the follow-up (p=0.60) or the
number of participants seen at each follow-up (Figure 1). All 1,300
participants were reviewed at 7 to 10 d. No participants in the silk
arm were recorded as not having their sutures removed at 7–10 d.
However, it was possible that incomplete removal could have
caused suture fragments to be left in situ. In these few participants
the individual conducting the participant’s next follow-up
examination was unmasked. 15 participants were not seen again
between 3 and 24 mo after surgery and were excluded from all
analyses: 11 from the silk arm and four from the polyglactin-910
arm.
Baseline Demographic and Clinical Characteristics
Baseline sociodemographic characteristics were balanced by
randomisation group (Table 1). All participants were Ethiopians of
Amharan ethnicity. Their mean age was 49.8 y and the majority
(78.1%) were female. Literacy rates and nutritional status (body
mass index) were comparable. Clinical features were also balanced
by randomisation group (Table 1). The baseline field and
photographic CO scores showed good correlation (linear weighted
kappa score 0.77; quadratic weighted kappa score 0.88; similar
agreement at 12 and 24 mo).
Trichiatic lashes touched the cornea in 1,049 (80.7%) eyes
(Table 1). Coexisting lower lid trichiasis was infrequent (13.3%).
In 204 (15.7%) participants no lashes were touching the eye on
the day of the baseline examination; however, all had clinical
evidence of epilation of more than five trichiatic lashes. There
was no significant difference in age or baseline disease severity
between the 15 individuals not seen after surgery and all other
participants.
Primary Outcome
At 12-mo follow-up, recurrent trichiasis was present in 221
study eyes and a further 13 participants had undergone repeat
surgery since baseline. Prevalence of recurrence was similar in the
two arms of the trial (18.2% [114/628] in the polyglactin-910
group versus 19.7% [120/608] in the silk group; OR=0.90, 95%
CI 0.68–1.20). The risk difference for any recurrent trichiasis
between the silk and polyglactin-910 arms was 20.016 (95% CI
20.059 to 0.023). The possibility of effect modification between
arm and other factors on the primary outcome was investigated;
none were significant, including surgeon.
Secondary Outcomes
There was no evidence of a difference in the rate of recurrence
between the two arms of the trial during the 2-y follow-up period
(hazard ratio = 0.99; 95% CI 0.82–1.21) (Figure 2). Of the 236
participants seen at 6 mo but not at 3 mo, 59 (25%) had recurrent
trichiasis and recurrence might have occurred earlier than 6 mo.
There was no evidence of differences in the other secondary
outcome measures at either 12 or 24 mo (Tables 2 and 3).
Recurrent trichiasis at 1 and 2 y was associated with more severe
entropion at baseline, tarsal conjunctival inflammation at baseline,
increasing age, and intersurgeon variability (Table 4).
Complications
Complications were observed in 219 participants (16.9%). The
overall complication risk was similar in the two arms of the trial
(silk 18.2% versus polyglactin-910 15.5%, p=0.21; Table 5) as
were risks of both intraoperative or early postoperative (7–10 d)
complications (Table 5). There was some evidence that some late
complications (after 7–10-d follow-up) were seen less frequently in
the polyglactin-910 group than the silk group: conjunctival
granulomas (OR=0.63, 95% CI 0.40–0.99, p=0.045) and suture
fragments in situ (OR=0.06, 95% CI 0.01–0.48, p=0.008).
Discussion
In this randomised controlled trial we tested the hypothesis that
absorbable sutures (polyglactin-910) reduce the recurrence of
trichiasis a year after surgery, compared with standard silk sutures
removed at 7 to 10 d. We found no evidence of a difference in
recurrence risk at either the primary endpoint (1 y) or over the 2-y
follow-up period. The risk difference between arms in the primary
end point was very small (1.1%) with narrow confidence intervals
(23.9% to 6.0%). This finding is consistent with the two sutures
being equivalent from a clinical perspective, although the trial was
not designed to test this hypothesis.
The relationship between suture type and trichiasis recurrence
was examined in a nonrandomised study from Egypt, which found
a significantly lower recurrence rate in cases where absorbable
sutures were used [11]. However, this lower rate may have been
partly due to confounding, as individuals who received absorbable
sutures were treated in the private sector, and environmental and
socioeconomic factors might have led to more severe preoperative
disease and increased risk of TT recurrence amongst those treated
in the public sector.
Our results suggest that, despite the lack of difference in
recurrence risk, there are operational reasons why a trachoma
control program might consider using absorbable sutures such as
polyglactin-910. Firstly, most individuals requiring TT surgery live
in relatively remote rural settings, and many are relatively old and
with limited financial resources. Under such conditions transport
may be limited or a significant financial burden, presenting a
major challenge for the patient to reattend a distant health facility
Trial of Absorbable Sutures for Trichiasis Surgery
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Figure 1. Trial profile.
doi:10.1371/journal.pmed.1001137.g001
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Table 1. Baseline characteristics and number of follow-up assessments of participants, by study arm.
Characteristic Silk, n=650 Polyglactin-910, n=650
n Percent or 95% CI n Percent or 95% CI
Gender (female) 508 (78.2%) 507 (78.0%)
Age
18–29 48 (7.4%) 60 (9.2%)
30–39 123 (18.9%) 127 (19.5%)
40–49 186 (28.6%) 159 (24.5%)
50–59 167 (25.7%) 160 (24.6%)
60–69 93 (14.3%) 112 (17.2%)
70+ 33 (5.1%) 32 (4.9%)
Mean (SD, 95% CI) 49.7 (12.9, 48.7–50.7) 49.9 (13.6, 48.9–51.0)
Illiterate 617 (94.9%) 625 (96.2%)
BMI, mean (SD, 95% CI) 20.1 (2.5, 19.9–20.3) 19.8 (2.3, 19.6–20.0)
Study eye (right)a 321 (49.4%) 352 (54.2%)
Best corrected LogMAR VA in study eye
20.2 to 0.3 193 (30.0%) 203 (31.6%)
0.3–0.7 248 (38.5%) 250 (38.9%)
0.7–1.1 104 (16.2%) 95 (14.8%)
1.1–2.0 29 (4.5%) 25 (3.9%)
CF/HM/PL 62 (9.6%) 59 (9.2%)
NPL 8 (1.2%) 10 (1.6%)
Not measurableb 6 8
Entropion grade
0 51 (7.9%) 69 (10.6%)
1 159 (24.5%) 153 (23.5%)
2 242 (37.2%) 248 (38.2%)
3 119 (18.3%) 98 (15.1%)
4 79 (12.2%) 82 (12.6%)
Trichiasis (number of lashes touching eye)
None (epilating) 106 (16.3%) 98 (15.1%)
1–5 (epilating) 253 (38.9%) 295 (45.4%)
6–9 152 (23.4%) 131 (20.2%)
10–19 89 (13.7%) 72 (11.1%)
20+ 50 (7.7%) 54 (8.3%)
Lower lid TT (present) 88 (13.5%) 85 (13.1%)
Corneal opacity
CC0, none 187 (28.8%) 194 (29.9%)
CC1, peripheral 181 (27.9%) 201 (30.9%)
CC2a, off centre faint 147 (22.6%) 119 (18.3%)
CC2b, off centre dense 26 (4.0%) 24 (3.7%)
CC2c, central faint 63 (9.7%) 68 (10.5%)
CC2d, central dense 18 (2.8%) 13 (2.0%)
CC3, total central dense 22 (3.4%) 28 (4.3%)
CC4, phthisis 6 (0.9%) 3 (0.5%)
Papillary inflammationc
None (P0) 52 (8.0%) 43 (6.6%)
Mild (P1) 183 (28.2%) 200 (30.8%)
Moderate (P2) 312 (48.1%) 304 (46.8%)
Severe (P3) 102 (15.7%) 103 (15.9%)
Conjunctival scarringc
None (C0) 0 (0.0%) 1 (0.1%)
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for suture removal. The use of absorbable sutures would eliminate
the need for an early postoperative review at 7 to 10 d, allowing
the service to focus on a more important 3- to 6-mo review to
check for recurrent trichiasis and provide repeat surgery.
Secondly, because not all patients will attend for routine follow-
up after surgery, retained sutures are not uncommon and can
cause significant trauma to the cornea. Even with the considerable
logistical resources (vehicles and personnel) available in this trial
and the high level of engagement by the participants in the follow-
up, we still found that 2.6% of people in the silk arm had
unremoved sutures at 3 mo. It is likely that this problem is
significantly more frequent under operational conditions. The use
of absorbable sutures generally avoids this problem. Whether a
trachoma control program adopts the use of absorbable sutures for
trichiasis surgery may be influenced by several locally specific
considerations, including the relative local costs of different sutures
types and the potential cost and time savings of not having to
arrange for early review and suture removal.
The trichiasis recurrence risk in our trial is at the lower end of
the range typically reported; 19% (234/1,236) of the trial eyes
Figure 2. Kaplan-Meier graph of time to failure.
doi:10.1371/journal.pmed.1001137.g002
Characteristic Silk, n=650 Polyglactin-910, n=650
n Percent or 95% CI n Percent or 95% CI
Mild (C1) 18 (2.8%) 12 (1.9%)
Moderate (C2) 400 (61.6%) 436 (67.1%)
Severe (C3) 231 (35.6%) 201 (30.9%)
Lagophthalmos (present) 20 (3.1%) 18 (2.8%)
n follow-up assessments
0 11 (1.7%) 4 (0.6%)
1 6 (0.9%) 6 (0.9%)
2 15 (2.3%) 12 (1.8%)
3 38 (5.8%) 39 (6.0%)
4 133 (20.5%) 135 (20.8%)
5 447 (68.8%) 454 (69.9%)
aParticipants with bilateral TT had one eye randomly selected as the trial eye.
bUnable to cooperate with visual acuity measurement.
cExamination of the tarsal conjunctiva was not possible in one individual.
CF, count fingers; BMI, body mass index; HM, hand movements; PL, perception of light; NPL, no perception of light; SD, standard deviation; VA, visual acuity.
doi:10.1371/journal.pmed.1001137.t001
Table 1. Cont.
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Table 2. Clinical characteristics of participants at 12 and 24 mo, by study arm.
Characteristic 12 mo 24 mo
Silk, n=628
Polyglactin-910,
n=608 Silk, n=609
Polyglactin-910,
n=609
Trichiasis (n lashes)
No trichiasisa 518 (82.5%) 496 (81.6%) 491 (80.6%) 492 (80.8%)
No lashes, epilating 15 (2.4%) 22 (3.6%) 23 (3.8%) 23 (3.8%)
1–5 84 (13.4%) 77 (12.7%) 87 (14.3%) 83 (13.6%)
6–9 7 (1.1%) 7 (1.1%) 5 (0.8%) 7 (1.1%)
10–19 2 (0.3%) 2 (0.3%) 2 (0.3%) 2 (0.3%)
20+ 2 (0.3%) 4 (0.6%) 1 (3.8%) 2 (0.3%)
Best corrected LogMAR VA in trial eye
20.2 to 0.3 184 (30.4%) 194 (30.9%) 167 (27.5%) 168 (27.6%)
0.3–0.7 250 (41.3%) 265 (42.3%) 257 (42.3%) 268 (44.1%)
0.7–1.1 89 (14.7%) 86 (13.7%) 107 (17.6%) 88 (14.5%)
1.1–2.0 32 (5.3%) 27 (4.3%) 27 (4.4%) 30 (4.9%)
CF/HM/PL 44 (7.3%) 48 (7.7%) 42 (6.9%) 45 (7.4%)
NPL 7 (1.2%) 7 (1.1%) 8 (1.3%) 9 (1.5%)
LogMAR change baseline to follow-up
.0.3 worse 49 (8.1%) 56 (9.1%) 57 (9.4%) 60 (10.0%)
0.1–0.3 worse 97 (16.1%) 111 (17.9%) 141 (23.3%) 131 (21.8%)
Within 0.1 (same) 270 (44.9%) 270 (43.6%) 248 (41.1%) 270 (45.0%)
0.1 to 0.3 better 118 (19.6%) 114 (18.4%) 92 (15.2%) 82 (13.7%)
.0.3 better 68 (11.3%) 68 (11.0%) 66 (10.9%) 57 (9.5%)
Entropion grade
0 550 (90.5%) 550 (87.6%) 538 (88.3%) 542 (89.0%)
1 34 (5.6%) 59 (9.4%) 44 (7.2%) 41 (6.7%)
2 16 (2.6%) 16 (2.6%) 22 (3.6%) 22 (3.6%)
3 6 (1.0%) 3 (0.5%) 4 (0.7%) 4 (0.7%)
4 2 (0.3%) 0 (0.0%) 1 (0.2%) 0 (0.0%)
Corneal opacity – field grading
CC0, none 219 (36.0%) 246 (39.2%) 231 (37.9%) 254 (41.7%)
CC1, peripheral 138 (22.7%) 154 (24.5%) 138 (22.7%) 136 (22.3%)
CC2a, off centre faint 143 (23.5%) 121 (19.3%) 133 (21.8%) 113 (18.6%)
CC2b, off centre dense 24 (4.0%) 21 (3.3%) 27 (4.4%) 21 (3.5%)
CC2c, central faint 50 (8.2%) 52 (8.3%) 48 (7.9%) 48 (7.9%)
CC2d, central dense 21 (3.5%) 17 (2.7%) 17 (2.8%) 14 (2.3%)
CC3, total central dense 9 (1.5%) 15 (2.4%) 12 (2.0%) 21 (3.5%)
CC4, phthisis 4 (0.7%) 2 (0.3%) 3 (0.5%) 2 (0.3%)
Corneal opacity change baseline to follow-up – photographic
grading
Worse 11 (1.8%) 6 (1.0%) 18 (3.0%) 24 (3.9%)
No change 510 (85.0%) 531 (85.0%) 499 (82.5%) 493 (81.1%)
Better 79 (13.2%) 88 (14.1%) 88 (14.5%) 91 (15.0%)
Corneal opacity change baseline to follow-up – field grading
.3 grades worse 1 (0.2%) 0 (0.0%) 1 (0.2%) 1 (0.2%)
3 grades worse 3 (0.5%) 0 (0.3%) 1 (0.2%) 1 (0.2%)
2 grades worse 10 (1.6%) 12 (1.9%) 11 (1.8%) 12 (2.0%)
1 grade worse 48 (7.9%) 53 (8.4%) 65 (10.7%) 45 (7.4%)
No change 413 (67.9%) 404 (64.3%) 375 (61.6%) 386 (63.4%)
1 grade better 93 (15.3%) 116 (18.5%) 108 (17.7%) 117 (19.2%)
2 grades better 37 (6.1%) 38 (6.1%) 43 (7.1%) 44 (7.2%)
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reexamined at 1 y had recurrent TT. Most trials or consecutive
series have reported similar 1-y TT recurrence risks in the range of
about 20% to 40% at 1 y [5–8,11,12,15]. An exception to this was
the STAR trial, also conducted in Ethiopia, which reported a
notably lower cumulative 1-y recurrence risk of 6.9% to 10.3%,
depending on intervention arm [13].
The reasons for recurrence are multiple. The time profile of
recurrence suggests that there are two distinct phases: (1) early
recurrence, occurring during the first 6 mo; (2) late recurrence,
which occurs from 6 mo onwards and develops at a reduced rate.
In the few prospective trials or case series with a year or more
follow-up, early recurrence has tended to account for the majority
of cases [5,8,9,12,13]. It is generally thought that this early
recurrence is largely determined by the preoperative disease
severity and how the surgery is performed in terms of both type
and quality of procedure.
We found that recurrent trichiasis at both 1 and 2 y was
significantly associated with both more severe entropion at
baseline and baseline conjunctival inflammation. Several studies
have found a consistent relationship between the severity of
preoperative disease (usually in terms of numbers of lashes or
entropion severity) and the risk of recurrence [8,12,13]. More
severely scarred eyelids are technically more challenging to
operate on and therefore the correction of the anatomical
abnormality may be less satisfactory or there may be a more
active underlying profibrotic disease state.
The type of operation performed also has a major effect on the
outcome. A systematic review of the alternative procedures that
have been compared in clinical trials found evidence to support
the use of procedures that involve a full thickness incision through
the tarsal plate, rotation of the distal fragment, and fixation with
everting sutures [4]. There are two commonly performed
alternative procedures: (1) BLRT and (2) PLTR. These procedures
have been compared head to head in a single trial with only
relatively short follow-up, which found equivalent recurrence rates
[23]. The WHO recommends the use of the BLTR in its
literature, but acknowledges that some programmes have chosen
to train their surgeons to use alternative procedures (such as the
PLTR), and that a switch to the BLTR is therefore not advised [3].
A large-scale randomised trial with long-term follow-up of these
two major alternatives in clinical practice would be of value.
The quality of the surgery is a major determinant of outcome.
We found significant variation in the recurrence risk between
surgeons. Surgeons were assigned to operate on patients on a
‘‘first-come-first-served’’ basis; therefore, it is unlikely that there
was selection bias in the severity of cases operated on by specific
surgeons in this trial. Moreover, intersurgeon variation persisted
after adjusting for baseline disease severity in the model. Several
other studies have found significant variation between surgeons,
Table 3. Univariate associations between outcome measures
and study arm (polyglactin-910 sutures compared to silk
sutures).
Outcome 12 mo 24 mo
OR 95% CI p-Value OR 95% CI p-Value
Recurrent trichiasis 0.90 0.68–1.20 0.48 0.99 0.78–1.25 0.90
Deterioration in
visual acuitya
1.20 0.88–1.65 0.25 1.04 0.78–1.39 0.78
Deterioration in
corneal opacity
1.02 0.70–1.47 0.93 0.73 0.51–1.05 0.09
Recurrent entropionb 1.34 0.94–1.93 0.11 0.94 0.66–1.33 0.72
Papillary
inflammation (P2/P3)
1.02 0.80–1.31 0.85 1.05 0.80–1.36 0.74
aDeterioration of two or more lines on LogMAR visual acuity chart.
bPresence of entropion, grade 2 or more.
doi:10.1371/journal.pmed.1001137.t003
Characteristic 12 mo 24 mo
Silk, n=628
Polyglactin-910,
n=608 Silk, n=609
Polyglactin-910,
n=609
3 grades better 2 (0.3%) 5 (0.8%) 2 (0.3%) 3 (0.5%)
.3 grades better 1 (0.2%) 0 (0.0%) 3 (0.5%) 0 (0.0%)
Papillary inflammation
None (P0) 152 (25.0%) 177 (28.2%) 333 (54.7%) 343 (56.3%)
Mild (P1) 277 (45.6%) 263 (41.9%) 130 (21.4%) 115 (18.9%)
Moderate (P2) 168 (27.6%) 178 (28.3%) 136 (22.3%) 138 (22.7%)
Severe (P3) 11 (1.8%) 10 (1.6%) 10 (1.6%) 13 (2.1%)
Lagophthalmos (present) 5 (0.8%) 6 (1.0%) 4 (0.7%) 1 (0.2%)
Recurrent TT by surgeonb
1 31/188 (16.5%) 28/177 (15.8%) 50/181 (27.6%) 54/175 (30.1%)
2 29/127 (22.8%) 33/124 (26.6%) 50/124 (40.3%) 49/124 (39.5%)
3 17/132 (12.9%) 16/127 (12.6%) 35/130 (26.9%) 37/130 (28.5%)
4 16/138 (11.6%) 23/134 (17.1%) 36/130 (27.7%) 33/133 (24.8%)
5 21/43 (48.8%) 20/46 (43.5%) 27/44 (61.4%) 27/47 (57.5%)
aIncludes individuals who had received repeat surgery, but had not developed a second episode of postoperative recurrence.
bDenominators are the number of cases performed by each surgeon, % values are the recurrences.
CF, count fingers; HM, hand movements; PL, perception of light; NPL, no perception of light; VA, visual acuity.
doi:10.1371/journal.pmed.1001137.t002
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suggesting that there might be subtle variations in technique that
influence the risk of recurrence [8,10,23]. Short incisions probably
lead to inadequate eversion and early recurrence; it has been
suggested that an incision of at least 20 mm should be used [24].
The degree of eversion at the end of the operation, regulated by
the positioning and tension of sutures, is probably a key
determinant of recurrent TT.
Late recurrent TT might occur owing to the immuno-fibrogenic
factors that caused conjunctival scarring and TT in the first place,
rather than problems directly related to the surgical procedure
[25]. A number of trials in different settings have investigated
whether the use of postoperative azithromycin can affect the
outcome. A study from Ethiopia found a significant reduction in
recurrence after antibiotic use whilst a study from The Gambia did
not. This difference might have been in part due to the difference
in exposure to Chlamydia trachomatis infection between participants
in the different trials [8,13].
Complications of trichiasis surgery are uncommon. There were
a few cases with moderate bleeding during surgery, all of whom
were managed successfully with firm pressure on the eyelid for a
few minutes. Similarly, postoperative wound infections were
uncommon and resolved rapidly with antibiotics. The only
Table 4. Univariate analysis and multivariable logistic regression models for any recurrent trichiasis at 1 or 2 y following surgery.
Variable 12 mo 24 mo
OR 95% CI p-Value OR 95% CI p-Value
Univariate analysis
Trial arm (silk) 1.06 0.82–1.36 0.67 0.99 0.78–1.25 0.90
Gender (female) 0.97 0.72–1.31 0.85 1.03 0.77–1.37 0.85
Age — — ,0.0001* — — ,0.0001*
18–30 1 — — 1 — —
30–39 1.27 0.71–2.28 — 1.27 0.74–2.19 —
40–49 1.77 1.02–3.08 — 1.49 0.89–2.50 —
50–59 1.66 0.95–2.89 — 1.98 1.18–3.33 —
60–69 2.73 1.53–4.86 — 2.72 1.57–4.71 —
70+ 2.17 1.02–4.59 — 2.11 1.02–4.35 —
Entropion at baseline (grade 3/4) 1.86 1.43–2.43 ,0.0001 1.65 1.28–2.13 ,0.0001
Baseline inflammation (P2/P3) 1.39 1.08–1.80 0.01 1.40 1.10–1.79 0.006
Surgeon (relative to surgeon 4) — — ,0.0001** — — ,0.0001**
1 0.99 0.68–1.44 — 1.16 0.81–1.66 —
2 1.93 1.32–2.84 — 1.87 1.28–2.72 —
3 0.87 0.57–1.32 — 1.08 0.73–1.58 —
4 1 — — 1 — —
5 4.86 2.92–8.09 — 4.10 2.49–6.77 —
Multivariable logistic regression models
Trial arm (silk) 1.09 0.84–1.42 0.52 0.98 0.77–1.26 0.90
Gender (female) 1.08 0.79–1.49 0.62 1.18 0.86–1.60 0.30
Age — — ,0.0001* — — ,0.0001*
18–30 1 — — 1 — —
30–39 1.25 0.68–2.28 — 1.22 0.70–2.15 —
40–49 1.81 1.02–3.22 — 1.50 0.88–2.56 —
50–59 1.71 0.96–3.05 — 2.09 1.23–3.57 —
60–69 3.11 1.71–5.67 — 3.06 1.73–5.38 —
70+ 2.38 1.08–5.23 — 2.30 1.08–4.89 —
Entropion at baseline (grade 3/4) 1.80 1.36–2.38 ,0.0001 1.59 1.22–2.09 0.0006
Baseline inflammation (P2/P3) 1.31 1.00–1.72 0.05 1.37 1.06–1.76 0.02
Surgeon (relative to surgeon 4) — — ,0.0001** — — ,0.0001**
1 1.02 0.70–1.51 — 1.17 0.81–1.69 —
2 2.00 1.34–2.95 — 1.88 1.28–2.76 —
3 0.87 0.57–1.32 — 1.06 0.71–1.57 —
4 1 — — 1 — —
5 4.93 2.93–8.29 — 4.13 2.48–6.89 —
*p-Value for trend.
**p-Value for heterogeneity.
doi:10.1371/journal.pmed.1001137.t004
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notable differences between the two trial arms occurred later:
retained suture and conjunctival granulomas (large enough to
obscure vision) were more common in lids where silk sutures had
been used. Silk is recognised to be quite proinflammatory in
operative wounds, which might explain the higher granulomas
rate.
This study has a number of strengths including the large size,
high follow-up rates, good balance of clinical and demographic
characteristics between the randomisation groups, the fact that
observations at each time point were made by a single observer,
and that outcome measures were determined by masked
individuals. There were slightly more individuals in the poly-
glactin-910 group who were lost to follow-up at 12 mo; however,
most of these participants had moved out of the study area and so
this small difference is not attributable to a treatment effect.
Despite careful standardisation procedures, there was still some
variation between the results of the different surgeons, indicating
the importance of how the surgery is performed. These may
include subtle variation in the length of the incision or the tension
on the everting sutures. Individuals with minor trichiasis were
excluded from this trial and enrolled into a separate trial
evaluating the efficacy of surgery versus epilation. However, we
are unaware of any reason to think that these findings could not be
generalised to the full range of trichiasis severity. It would be
interesting to know if there were significant differences in the
participants’ experience of the different sutures used in this trial
and their perspectives on the potential benefit of not needing to
have the absorbable sutures removed; however, we did not
formally investigate this. Detecting differences in changes in both
corneal disease and visual acuity would probably require a longer
follow-up period.
Polyglactin-910 absorbable sutures had a similar risk of trichiasis
recurrence to silk sutures for PLTR TT surgery and comparable
secondary outcomes. However, from a programmatic perspective,
polyglactin-910 offers the major advantage that patients do not
have to be seen soon after surgery for suture removal. The
postoperative review can be delayed for 3–6 mo, which might
allow us to better determine who needs additional surgery and
offset the slightly higher cost of absorbable sutures. The logistical
advantages of using absorbable sutures should be taken into
consideration when considering the choice of suture material.
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Editors’ Summary
Background. Globally, around 40 million people—mostly
people living in rural areas in developing countries where
there are water shortages, poor personal hygiene, and
crowded living conditions—have active trachoma, an
infectious eye disease that is caused by Chlamydia
trachomatis. This bacterium is spread through contact with
infected eye secretions or with contaminated towels or
clothes, and by flies. Recurrent infections with C. trachomatis
during early childhood cause inflammation of the tissue
lining the eye lid (chronic conjunctival inflammation), which
can lead to conjunctival scarring. If this scarring is severe, the
eyelids turn inwards (entropion) and the lashes rub across
the eye’s surface (the cornea). This condition—trachomatous
trichiasis—is extremely painful and, if not treated with
surgery, can lead to irreversible corneal opacities and visual
impairment by middle age. It is estimated that 8 million
people have trichiasis and that an additional 8 million people
are blind or visually impaired as a result of the condition.
Why Was This Study Done? Surgery for trichiasis,
antibiotics for infection, and facial cleanliness and
environmental improvements to reduce transmission
together constitute the SAFE strategy for the control of
blinding trachoma. Unfortunately, trichiasis recurs in nearly
two-thirds of patients within 3 years of surgery, often within
the first year. How the surgery is performed, its quality, and
the severity of entropion and conjunctival scarring at the
time of surgery all contribute to trichiasis recurrence. In this
randomized trial (a study in which randomly chosen groups
of patients receive different treatments for a disease and are
followed to compare the outcomes of these interventions),
the researchers investigate whether using absorbable
sutures instead of silk sutures reduces the risk of recurrent
disease among patients with major trichiasis (more than five
lashes touching the cornea). Sutures are used to sew up
surgical incisions. Silk sutures, which are used routinely
during trichiasis surgery, have to be removed 7–10 days after
surgery when the incision may not have stably healed.
Absorbable sutures might provide more stable fixation of the
eye tissue while healing is taking place and might, therefore,
reduce the recurrence of trichiasis after surgery.
What Did the Researchers Do and Find? The researchers
randomly assigned 1,300 people living in Ethiopia (the
country with the highest rates of trachoma and trichiasis) to
receive trichiasis surgery using silk sutures (removed at 7–10
days) or absorbable sutures (left in place); the other details of
the surgery were identical for all the patients. The trial’s
primary outcome was recurrent trichiasis (one or more lash
touching the eye) at 1 year. Secondary outcomes included
the rate of recurrence, visual acuity, corneal opacity, and
conjunctival inflammation at 2 years, and surgical
complications. At 1 year, 18.2% of the patients in the
absorbable suture group and 19.7% in the silk suture group
had developed recurrent trichiasis. That is, the prevalence of
recurrence in the two groups was similar. There was also no
difference in the rate of trichiasis recurrence between the
groups 2 years after surgery. Moreover, the two groups did
not differ in terms of corneal opacity and visual acuity,
conjunctival inflammation, or surgical complications.
What Do These Findings Mean? These findings provide
no evidence to suggest that the use of absorbable sutures
during trichiasis surgery is clinically better than the use of silk
sutures. However, the researchers note that the use of
absorbable sutures would eliminate the need for patients to
return to the clinic soon after their operation to have their
sutures removed. In remote rural settings, it can be difficult
for patients, who are often elderly and poor, to attend clinics.
Thus, it might be better for trachoma services to concentrate
on encouraging patients to return 3–6 months after surgery
when the need for additional surgery can be determined
rather than trying to encourage them to come back after 7–
10 days for suture removal. The use of absorbable sutures
would also avoid any complications arising from patients
failing to come back to have their stitches removed. The
researchers suggest, therefore, that trachoma control
programs should now consider the potential logistical
advantages of using absorbable sutures rather than silk
sutures during trichiasis surgery despite the lack of any
apparent clinical difference between the two suture types.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001137.
N An accompanying PLoS Medicine Research Article by Saul
Rajak et al. describes another randomized trial undertaken
by these researchers that compares surgery and epilation
(eyelash removal) for the treatment of trichiasis in Ethiopia
N The World Health Organization has information on
trachoma (in several languages), including details of the
Alliance for Global Elimination of Trachoma by the year
2020 (GET 2020) and a personal story about blinding
trachoma
N The UK National Health Service Choices website also
provide information on trachoma
N Orbis, an international nonprofit organization devoted to
blindness prevention and treatment in developing coun-
tries, provides information about trachoma
N The International Trachoma Initiative provides detailed
information about trachoma and a personal story about
trichiasis surgery in Ethiopia
N The Global Atlas of Trachoma is an open-access resource
on the geographical distribution of trachoma
N Light for the World is a nonprofit organization dedicated to
ensuring the rights of persons with disabilities in
developing countries, including people in Ethiopia with
trachoma
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